WILMINGTON, Del. — Positive results from the EMERALD-1 Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with TACE and bevacizumab demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (PFS) compared to TACE alone in patients with hepatocellular carcinoma (HCC) eligible for embolization....
research News
Barcelona, Spain – Pancreatic cancer is one of the most aggressive cancers and has one of the lowest survival rates—only 10% after five years. One of the factors contributing to its aggressiveness is its tumor microenvironment, known as the stroma, which makes up the majority of the tumor mass and...
LUND, Sweden — Hansa Biopharma today announced full results from the 16-HMedIdeS-12 phase 2 trial in patients with antibody mediated rejection (AMR) episodes following a kidney transplant demonstrating that imlifidase significantly reduced donor-specific antibodies (DSAs) within the first five days of treatment. In the trial, the primary endpoint was the...
Utrecht, Netherlands – A detailed ‘atlas’ of neuroblastoma tumors points to a new target for immunotherapy. Scientists from the Princess Máxima Center for pediatric oncology in the Netherlands mapped this childhood tumor at the level of individual cancer and immune cells. In doing so, they discovered a brake on the...
ROYAL OAK, Mich. — IMMUNIS.AI, an immunogenomics company developing blood-based cancer surveillance technologies, today announced that results from a prostate cancer risk stratification study evaluating the company’s novel blood-based liquid biopsy platform were published in The Journal of Urology. The results validate the ability of the platform to accurately stratify...
JERUSALEM, Israel — Immunity Pharma, a clinical-stage neurology-focused biopharmaceutical company, today announced positive top line results from the Phase 2a trial with IPL344 in amyotrophic lateral sclerosis (ALS) patients. The study demonstrated statistically significant efficacy as measured by change in the slope decline of ALSFRS-R. The drug was well tolerated, and the...
Barcelona, Spain – Patients with metastatic or recurrent cervical cancer not amenable to curative surgery and/or radiotherapy have a poor prognosis with limited treatment options. First-line treatment in this setting consists of combination cisplatin/paclitaxel chemotherapy plus antiangiogenic agent bevacizumab. This therapeutic strategy was approved based on the results of the...
Baltimore, Maryland – People with operable non-small cell lung cancers may fare better over the next few years by receiving immunotherapy treatments before and after surgery instead of only before surgery, according to a new analysis by Johns Hopkins Kimmel Cancer Center investigators. For the study, researchers compared health outcomes among 147...
Boston, Mass. – For the first time in fifty years, results from a phase 3 randomized, placebo-controlled trial have shown an overall survival benefit from an adjuvant therapy in patients with kidney cancer. Treatment with pembrolizumab, an immunotherapy drug, after surgery significantly prolonged overall survival in patients with clear-cell renal-cell...
VANCOUVER, BC — According to the European Cancer Information System (ECIS), new cancer cases and deaths are on the rise in the EU. Sadly, this is a trend that’s happening in North America too, especially among young people. Perhaps the most concerning are the incidences of pancreatic cancer, which while...